Life Sciences & Biotechnology Strategy
February 24, 2021
On February 24th, EuropaBio submitted its feedback to the HERA Consultation.
February 15, 2021
Read EuropaBio Report ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’
February 12, 2021
On February 4th, Alexion continued its RareConversations event series in cooperation with EuropaBio.
February 12, 2021
EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
February 2, 2021
The purpose of this study is to estimate the economic impact of the production activities of European enterprises applying biotechnology in their research and manufacturing processes.
January 29, 2021
EuropaBio welcomes the European Health Union plan. The EU has indeed a critical role to play in public health and better crisis preparedness to address serious cross-border health threats and improving crisis management capacity.
January 28, 2021
Read the European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation.
January 20, 2021
Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
November 30, 2020
Call for more effective EU regulation of clinical trials with Advanced Therapy
Medicinal Products consisting of or containing Genetically Modified Organisms
November 25, 2020
EuropaBio looks forward to working closely with the European institutions to ensure the Pharmaceutical Strategy delivers for European patients and establishes a framework that enables a successful life sciences sector for the medium to long-term.
November 2, 2020
EuropaBio announces Dr. Claire Skentelbery as new Director General of the Association.
October 20, 2020
By putting forward these recommendations, EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
October 20, 2020
EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
October 19, 2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
October 2, 2020
As Europe looks to the implementation of the EU Green Deal and a sustainable post-COVID future, this year’s conference will highlight how industrial biotechnology and bio-based innovation can play a key role in the transition to a more sustainable and circular economy.